Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CELC NASDAQ:DAVE NASDAQ:TDUP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCELCCelcuity$138.23$121.56$10.26▼$151.02$6.74B0.091.26 million shs661,189 shsDAVEDave$228.46$223.68$152.21▼$287.69$2.90B3.93431,683 shs459,887 shsTDUPThredUp$4.29$3.96$3.08▼$12.28$553.59M2.072.78 million shs1.15 million shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCELCCelcuity0.00%+0.40%+14.21%+31.46%+1,224.04%DAVEDave0.00%-3.11%-16.79%+37.97%+15.66%TDUPThredUp0.00%+4.63%+1.90%-4.45%-41.87%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCELCCelcuity$138.23$121.56$10.26▼$151.02$6.74B0.091.26 million shs661,189 shsDAVEDave$228.46$223.68$152.21▼$287.69$2.90B3.93431,683 shs459,887 shsTDUPThredUp$4.29$3.96$3.08▼$12.28$553.59M2.072.78 million shs1.15 million shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCELCCelcuity0.00%+0.40%+14.21%+31.46%+1,224.04%DAVEDave0.00%-3.11%-16.79%+37.97%+15.66%TDUPThredUp0.00%+4.63%+1.90%-4.45%-41.87%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCELCCelcuity 2.83Moderate Buy$149.308.01% UpsideDAVEDave 2.93Moderate Buy$325.8842.64% UpsideTDUPThredUp 2.86Moderate Buy$9.14113.05% UpsideCurrent Analyst Ratings BreakdownLatest CELC, DAVE, and TDUP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2026DAVEDave Barrington ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$290.005/19/2026CELCCelcuity Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/18/2026CELCCelcuity HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$165.00 ➝ $185.005/15/2026CELCCelcuity Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$150.00 ➝ $183.005/15/2026CELCCelcuity Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$157.005/11/2026DAVEDave Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C+) ➝ Buy (B-)5/6/2026DAVEDave Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$332.005/6/2026DAVEDave Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$328.00 ➝ $342.005/6/2026DAVEDave CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/6/2026DAVEDave Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$335.00 ➝ $365.005/5/2026TDUPThredUp TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$5.00 ➝ $5.70(Data available from 5/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCELCCelcuityN/AN/AN/AN/A$1.10 per shareN/ADAVEDave$554.20M5.24$12.87 per share17.75$16.03 per share14.25TDUPThredUp$310.81M1.78N/AN/A$0.46 per share9.33Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCELCCelcuity-$177.04M-$3.90N/A3,455.75N/AN/A-244.61%-50.22%8/13/2026 (Estimated)DAVEDave$195.87M$15.5514.6913.08N/A37.22%77.70%45.59%8/5/2026 (Estimated)TDUPThredUp-$20.21M-$0.16N/AN/AN/A-6.68%-36.11%-12.53%8/3/2026 (Estimated)Latest CELC, DAVE, and TDUP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026CELCCelcuity-$1.07-$0.97+$0.10-$0.97$2.94 millionN/A5/5/2026Q1 2026DAVEDave$2.86$3.64+$0.78$4.02$153.67 million$158.40 million5/4/2026Q1 2026TDUPThredUp-$0.05-$0.05N/A-$0.05$80.17 million$81.67 million3/25/2026Q4 2025CELCCelcuity-$1.06-$0.97+$0.09-$0.97$1.28 millionN/A3/2/2026Q4 2025TDUPThredUp-$0.04-$0.04N/A-$0.04$77.17 million$79.70 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCELCCelcuityN/AN/AN/AN/AN/ADAVEDaveN/AN/AN/AN/AN/ATDUPThredUpN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCELCCelcuity6.0412.3112.31DAVEDave0.953.863.86TDUPThredUp0.300.950.95Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCELCCelcuity63.33%DAVEDave18.01%TDUPThredUp89.08%Insider OwnershipCompanyInsider OwnershipCELCCelcuity13.33%DAVEDave28.48%TDUPThredUp23.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCELCCelcuity4048.77 million42.27 millionOptionableDAVEDave25012.71 million9.09 millionOptionableTDUPThredUp2,132129.04 million99.23 millionOptionableCELC, DAVE, and TDUP HeadlinesRecent News About These CompaniesHow ThredUp (TDUP) Narrative Is Shifting As Analysts Recut Targets And Reassess Upside3 hours ago | finance.yahoo.comBloombergSen Inc. Has $8.14 Million Position in ThredUp Inc. $TDUPMay 23 at 3:36 AM | marketbeat.comFunko, ThredUp, Xponential Fitness, Offerpad, and Caleres shares are soaring, what you need to knowMay 20, 2026 | msn.comThredUp to Participate in TD Cowen and William Blair Investor ConferencesMay 20, 2026 | globenewswire.comHere’s Optimist Fund’s Views on ThredUp (TDUP)May 19, 2026 | insidermonkey.comThredUp Inc. (NASDAQ:TDUP) Given Consensus Recommendation of "Moderate Buy" by AnalystsMay 18, 2026 | americanbankingnews.comThredUp and Malibu Boats Stocks Trade Down, What You Need To KnowMay 16, 2026 | finance.yahoo.comThredUp (TDUP) Slides After Disappointing Quarterly Results Despite Strong Prior RunMay 13, 2026 | insidermonkey.comThredUp (TDUP) Slides After Disappointing Quarterly Results Despite Strong Prior RunMay 13, 2026 | uk.finance.yahoo.comThe 5 most interesting analyst questions from ThredUp’s Q1 earnings callMay 11, 2026 | msn.comFY2026 EPS Estimates for ThredUp Cut by Northland SecuritiesMay 11, 2026 | marketbeat.comNorthland Securities Keeps Their Buy Rating on thredUP (TDUP)May 10, 2026 | theglobeandmail.comEquities Analysts Offer Predictions for ThredUp Q3 EarningsMay 8, 2026 | marketbeat.comThredUp Inc. 2026 Q1 - Results - Earnings Call PresentationMay 7, 2026 | seekingalpha.comAnalysts Are Bullish on These Consumer Cyclical Stocks: thredUP (TDUP), Ferrari (RACE)May 7, 2026 | theglobeandmail.comAnalysts Are Bullish on These Consumer Cyclical Stocks: thredUP (TDUP), DoorDash (DASH)May 6, 2026 | theglobeandmail.comAnalysts Have Conflicting Sentiments on These Consumer Cyclical Companies: thredUP (TDUP), Home Depot (HD) and Allison Transmission Holdings (ALSN)May 6, 2026 | theglobeandmail.comThredUp Doubles Down on Resale-as-a-Service® (RaaS®); Appoints Strategic Advisory Board to Scale Universal Recommerce LayerMay 6, 2026 | globenewswire.comThredUp Q1 Loss Meets Estimates, Adjusted EBITDA Margin ShrinksMay 5, 2026 | zacks.comThredUp (NASDAQ:TDUP) Shares Gap Up - Here's WhyMay 5, 2026 | marketbeat.comTDUP Q1 deep dive: Buyer growth and AI initiatives offset macro headwindsMay 5, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCELC, DAVE, and TDUP Company DescriptionsCelcuity NASDAQ:CELC$138.23 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$136.50 -1.73 (-1.25%) As of 05/22/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.Dave NASDAQ:DAVE$228.46 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$227.00 -1.46 (-0.64%) As of 05/22/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Dave, Inc. is a digital banking service. Its products include a budgeting tool to help members manage their upcoming bills to avoid overspending, cash advances through its flagship ExtraCash product to help members avoid punitive overdraft fees, a Side Hustle product, where Dave helps connect members with supplemental work opportunities, and Dave Banking, a modern checking account experience with valuable tools for building long-term financial health. The company was founded by Jason Wilk, Paras Chitrakar, and John Wolanin in October 2015 and is headquartered in Los Angeles, CA.ThredUp NASDAQ:TDUP$4.29 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$4.36 +0.08 (+1.75%) As of 05/22/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ThredUp Inc., together with its subsidiaries, operates an online resale platform in the United States and internationally. Its platform enables consumers to buy and sell primarily secondhand apparel, shoes, and accessories. ThredUp Inc. was incorporated in 2009 and is headquartered in Oakland, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Ross Stores Earnings Beat Sends Stock To New Highs Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins Apparel Earnings Winners and Losers: Ralph Lauren Takes Off SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? The Careful Consumer: What Q1 Earnings Reveal—And Where Cracks May Appear Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
